AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02176538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Product 0405
Description: Placebo for Product 0405 will be administered topically twice daily for 28 days.
Study NCT03431922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endovascular denervation
Description: multi-electrode catheter-based endovascular denervation
Study NCT05862194 — intervention group
Intervention type: DRUG
Intervention: Lazertinib
Description: Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
Study NCT05862194 — intervention group
Intervention type: DRUG
Intervention: Platinum-based Chemotherapy
Description: Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period
Study NCT02103270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Protein 4,000mg
Description: Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity.
Study NCT02103270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oat Flour
Description: Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study).
Study NCT02103270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oat Flour
Description: Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study).
Study NCT02103270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Protein 300 mg
Description: Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study).
Study NCT02151929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold
Description: stenting of an acute thrombotic lesion in patient within STEMI
Study NCT02327065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA (EchoTip Ultra)
Description: FNA,Fine needle aspiration
Study NCT02327065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB (EchoTip ProCore)
Description: FNB,Fine needle biopsy
Study NCT03642457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 cc 0.5%
Study NCT02151929 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent
Description: stenting of an acute thrombotic lesion in patient within STEMI
Study NCT03642457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine liposome
Description: 133mg liposomal bupivacaine
Study NCT00647543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
Study NCT03244423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline at induction
Description: 0.5 ml/kg
Study NCT03244423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline at induction
Description: 0.5 ml/kg
Study NCT03244423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: 1ml/kg/hr. during surgery for six hours
Study NCT03244423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline infusion
Description: 1ml/kg/hr. during surgery for six hours
Study NCT03244423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tranexamic acid
Description: 50 mg/kg
Study NCT03244423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infusion tranexamic acid
Description: 1mg/kg/hr infusionfor 6 hours
Study NCT03244423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical tranexamic acid
Description: 50 mg/kg added to the normal saline 2 ml/kg into the pericardial cavity before sternal closure
Study NCT03244423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical normal saline
Description: 2 ml/kg into the pericardial cavity before sternal closure
Study NCT03244423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical normal saline
Description: 2 ml/kg into the pericardial cavity before sternal closure
Study NCT02021253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Lactibiane TOLERANCE vs Placebo
Study NCT02021253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04154150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Description: Single subanesthetic infusion of ketamine (0.5mg/kg)
Study NCT04154150 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous ketamine
Description: Single subanesthetic infusion of ketamine (0.5mg/kg)
Study NCT04154150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: 8 sessions of computer-based cognitive training
Study NCT03642457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine liposome
Description: 133mg liposomal bupivacaine
Study NCT01301677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone liquid formulation
Study NCT01301677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2PX+
Description: strontium chloride hexahydrate in a penetration enhancing vehicle
Study NCT01301677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2PX-
Description: strontium chloride hexahydrate without a penetration enhancing vehicle
Study NCT03431454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trained to do the pencil push-ups procedure
Description: 15 minutes per day, five days a week
Study NCT03431454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: using a major amblyoscope twice weekly with additional home orthoptic therapy
Description: 60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed.
Study NCT04154150 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: 8 sessions of computer-based sham training
Study NCT03431454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: using three diopter over-minus lenses and a base out prism
Description: For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
Study NCT01674790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
Study NCT01674790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
Study NCT01674790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Range of motion exercise
Description: One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
Study NCT01674790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unstructured mental activity
Description: One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
Study NCT00530881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PHX1149
Study NCT04144660 — intervention group
Intervention type: DEVICE
Intervention: Extracorporeal Membrane Oxygenation
Description: Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.
Study NCT02570074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Broad spectrum antibiotic
Study NCT01853436 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Strattice™ Reconstructive Tissue Matrix
Description: Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
Study NCT02469792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Study NCT02469792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRC isolation
Description: ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
Study NCT04073056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine Hcl 0.25% Inj
Study NCT02724241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one time exposure to e-cig with nicotine
Description: one time exposure to e-cigarette vapor with nicotine
Study NCT02724241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One time exposure to e-cigarette without nicotine
Description: One time exposure to e-cig without nicotine
Study NCT02724241 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: one time exposure to empty e-cigarette
Description: one time exposure to empty e-cigarette (sham control)
Study NCT03702179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
Study NCT03702179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
Study NCT03702179 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder.
Study NCT04401774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given every 4 weeks at 480mg flat dose intravenously for one year (total of 13 nivolumab doses).
Study NCT02180828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal tablet
Description: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Study NCT02469792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Study NCT03307681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White bread
Description: Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
Study NCT03307681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baked potato with skin
Description: Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
Study NCT03307681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mashed potato served hot
Description: Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
Study NCT03307681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fried French fries
Description: Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
Study NCT03307681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal skipping
Description: No food given
Study NCT03677921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Investigational Product (Bio-Germanium)
Description: * Ingredient: Bio-Germanium~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks
Study NCT03677921 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group - Placebo Product
Description: * Ingredient: Corn starch~* Type: HPMC capsule~* Weight: 300mg/capsule~* Directions: 2 capsules, twice a day~* Storage: Room temperature (below 25℃)~* Duration of use: 8 weeks
Study NCT00926328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan, fluoride
Description: Six Month study, brush twice daily
Study NCT00926328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: twice daily usage
Study NCT04194580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phisical activity intervention
Description: The prevalence of overweight in chilean children in the among the highest in the world and increasing quickly. The investigators recently evaluated an after-school program of recreational physical activity to control overweight, obesity and other cardiovascular risk factors in primary school children Temuco. This program reduced adiposity and increased the fitness.
Study NCT02180828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: 2 doses of 150 mg oral Fluconazole (at day1 and day4)
Study NCT01364649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Vortioxetine tablets
Study NCT01364649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram tablets
Study NCT02469792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraarticular administration of autologous ADRC
Study NCT01364649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vortioxetine Placebo-matching capsules
Study NCT00903396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Given IV
Study NCT00903396 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given IV
Study NCT04018196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery as training manual task
Description: They will have a motor imagery as training manual task for 30 minutes. They will have 3 tests for performing manual task before training (pretest) and after training (post-test).
Study NCT04018196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor imagery as training motor task
Description: They will have a motor imagery as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test).
Study NCT04018196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: emotionally neutral film as training of manual task
Description: They will have to watch an emotionally neutral as training manual task for 30 minutes before performing this task.~They will have 3 tests for performing manual task before training (pretest) and after training (post-test).
Study NCT04018196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: emotionally neutral film as training of motor task
Description: They will have to watch an emotionally neutral as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test).
Study NCT04291872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass -Ionomer Cement with /without Led Light Cure
Description: Teeth were restored as same protocole with non-Heated Group. LED light (GC- D-Light DUO) was used at standard mode 1200 mW/cm2, at 50-60 ºC, for 60 sec.
Study NCT00613782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reandron 1000
Description: 1000mg at 0,6,18,30 weeks
Study NCT00613782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo injection 0,6.18.30 weeks
Study NCT03346616 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Texting Group
Description: See above in arm/group description
Study NCT03346616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Texting Group
Description: See above in arm/group description
Study NCT06044467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-human CCL24 monoclonal antibody (CM-101) - Part One
Description: Anti-human CCL24 monoclonal antibody (CM-101) - Part One
Study NCT06044467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
Description: Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
Study NCT03868410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New rTMS Approach
Description: Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
Study NCT03868410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rTMS Approach
Description: Participants in this arm will receive rTMS-based facilitation of the ipsilesional primary motor cortex (iM1) before the start of each session. iM1 will be stimulated with high-frequency rTMS (5-Hz) using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 2 days a week for 6 weeks, i.e., for a total of 12 sessions.
Study NCT00765440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: therapeutic nutritional supplementation
Description: Given orally
Study NCT00765440 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00765440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study NCT00697658 — intervention group
Intervention type: DRUG
Intervention: Paliperidone ER
Description: 6 mg tablet once daily, variable treatment length.
Study NCT01653158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-751,871
Description: CP-751,871 was given intravenously \[IV\] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.~Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year).
Study NCT01653158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel up to 75 mg/m\^2 was administered intravenously \[IV\] on Day 1 of each 3-week dosing cycle.
Study NCT02999568 — intervention group
Intervention type: OTHER
Intervention: Physical exercise
Description: Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
Study NCT04777214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Active TMS will be at 90% motor threshold
Study NCT04777214 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham TMS will be administered